Contact Us

Tysabri
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


MULTIPLE SCLEROSIS DRUG (TYSABRI) MAY HAVE BEEN RESPONSIBLE FOR FOURTH DEATH FROM RARE BRAIN DISEASE

Jun 3, 2005 | www.Newsinferno.com

The FDA has been informed by Biogen Idec Inc. that a fourth person may now have died from a rare brain disease known as progressive multifocal leukoencephalopathy (PML) after being treated with its multiple sclerosis drug Tysabri. Biogen and its development partner, Elan Corp. PLC of Ireland, had hoped to return the drug to the market despite three previous deaths from PML which had led to the suspension of the drug on February 28 of this year.

The latest death, if linked to Tysabri, may prove to be an insurmountable obstacle to that plan. Word of that death caused shares of Elan’s stock to plummet in value yesterday.


Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo